• Publications
  • Influence
Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer
Background Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration‐resistant prostate cancer. We evaluated the clinical benefitExpand
  • 798
  • 44
  • PDF
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a
BACKGROUND Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistantExpand
  • 755
  • 22
  • PDF
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
BACKGROUND Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions.Expand
  • 210
  • 9
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
PURPOSE To perform a phase II study of the farnesyl transferase inhibitor R115777 (Zarnestra; Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ) in patients withExpand
  • 152
  • 4
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
At present, there is no method available to predict response to farnesyltransferase inhibitors (FTIs). We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study ofExpand
  • 124
  • 4
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
This phase 3, multicenter, open-label study evaluated the efficacy and safety of tipifarnib compared with best supportive care (BSC), including hydroxyurea, as first-line therapy in elderly patientsExpand
  • 131
  • 3
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
This multicenter phase 2 study evaluated the use of tipifarnib (R115777) in patients with poor-risk myelodysplastic syndrome (MDS; French-American-British classification). Patients (n = 82) receivedExpand
  • 98
  • 3
  • PDF
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†
Resistance to nonsteroidal aromatase inhibitors is a major obstacle in the management of estrogen receptor-positive postmenopausal metastatic breast cancer. The addition of abiraterone acetate toExpand
  • 44
  • 3
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
BACKGROUND In the final analysis of the phase 3 COU-AA-301 study, abiraterone acetate plus prednisone significantly prolonged overall survival compared with prednisone alone in patients withExpand
  • 37
  • 3
  • PDF
Abiraterone acetate for metastatic castration‐resistant prostate cancer after docetaxel failure: A randomized, double‐blind, placebo‐controlled phase 3 bridging study
  • Y. Sun, Q. Zou, +13 authors D. Ye
  • Medicine
  • International journal of urology : official…
  • 1 May 2016
To evaluate the efficacy and safety of abiraterone acetate‐prednisone versus placebo‐prednisone in Asian metastatic castration‐resistant prostate cancer patients who have failed docetaxel‐basedExpand
  • 15
  • 3